Estimaciones de analistas de Wall Street para Cerus Corporation (CERS): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.01 | ||
| 2026-07-30 | $-0.01 | $-0.01 | +25.0% |
| 2026-04-30 | $-0.01 | $-0.03 | +66.7% |
| 2026-03-02 | $-0.01 | $-0.01 | +0.0% |
| 2025-11-06 | $-0.00 | $-0.02 | +99.5% |
| 2025-08-05 | $-0.03 | $-0.02 | -50.0% |
| 2025-05-01 | $-0.04 | $-0.05 | +20.0% |
| 2025-02-20 | $-0.01 | $-0.01 | +0.0% |
Ratios de valoración
| Precio / Valor contable | 6.88 |
| EV / EBITDA | 192.78 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $37.2M | $43.6M | $60.9M | $74.6M | $91.9M | $130.9M | $162.0M | $156.4M | $180.3M | $206.1M |
| Coste de Ventas | $20.3M | $22.5M | $31.6M | $33.4M | $41.2M | $63.5M | $75.0M | $70.0M | $80.7M | $93.8M |
| Beneficio Bruto | $16.9M | $21.0M | $29.3M | $41.2M | $50.8M | $67.4M | $87.1M | $86.4M | $99.5M | $112.3M |
| I+D | $31.3M | $33.7M | $42.6M | $60.4M | $64.4M | $63.7M | $64.1M | $67.6M | $58.9M | $67.7M |
| Generales y Administrativos | $48.8M | $52.4M | $56.8M | $66.2M | $67.0M | $81.3M | $83.3M | $75.5M | $75.9M | $80.9M |
| Gastos Operativos | $78.2M | $78.6M | $84.3M | $107.5M | $109.1M | $116.3M | $121.2M | $116.5M | $113.7M | $121.0M |
| Beneficio Operativo | -$61.4M | -$57.5M | -$55.0M | -$66.2M | -$58.3M | -$48.9M | -$34.1M | -$30.1M | -$14.2M | -$8.7M |
| EBITDA | -$58.5M | -$51.9M | -$51.9M | -$64.6M | -$51.4M | -$46.0M | -$33.5M | -$26.3M | -$10.0M | -$5.5M |
| Gastos por Intereses | $2.4M | $3.0M | $4.0M | $6.1M | $3.7M | $4.9M | $5.8M | $8.4M | $8.9M | $8.3M |
| Beneficio Antes de Impuestos | -$62.7M | -$56.7M | -$57.3M | -$71.0M | -$59.6M | -$54.1M | -$42.3M | -$37.3M | -$20.8M | -$15.3M |
| Impuestos | $175000 | $3.9M | $229000 | $263000 | $284000 | $319000 | $488000 | $325000 | $205000 | $354000 |
| Beneficio Neto | -$62.9M | -$60.6M | -$57.6M | -$71.2M | -$59.9M | -$54.4M | -$42.8M | -$37.5M | -$20.9M | -$15.6M |
| BPA | $-0.62 | $-0.56 | $-0.44 | $-0.51 | $-0.37 | $-0.32 | $-0.24 | $-0.21 | $-0.11 | $-0.08 |
| BPA Diluido | $-0.62 | $-0.56 | $-0.44 | $-0.51 | $-0.37 | $-0.32 | $-0.24 | $-0.21 | $-0.11 | $-0.08 |
| Acciones en Circulación (Diluidas) | $101.8M | $108.2M | $131.7M | $139.8M | $163.9M | $171.3M | $176.5M | $180.3M | $184.6M | $190.6M |
Precio
| Precio | $2.53 |
| Capitalización | $510M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: CVRX · MASS · NPCE · QTRX · RXST · SENS · SGHT
Explorar sector: Healthcare · Medical - Devices
Más secciones de CERS: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones